30th June BioBreakfast – Strategies for China: Managing Risk to Build Opportunity

China is undergoing a massive transformation in healthcare, with the Chinese Government accelerating progress to address rising levels of chronic disease and support an ageing population. Combined with a burgeoning middle class that is fueling economic growth, there is huge demand for smarter more accessible healthcare solutions.

This is creating great opportunities for Victorian organisations with innovative products who are interested in developing business strategies to collaborate with China and access new commercial markets.

Date:  Friday 30th June 2017

Time:  Registration from 7:20am for a 7.30am breakfast networking followed by presentations and discussion from 8.00am – 9:00am

Venue:  The Cube, ACMI, Federation Square, Melbourne

Cost:
Members: $65
Non-Members: $130
(Prices include GST)

To check if your organisation is a member, click here

Cancellation Policy:
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event

Register here

Panellist: 

Tom Ellis,  Investment Director at MAI Capital.  

Tom will join the panel discussion and share his insights into pathways as well as barriers to entry for the Chinese market.  You can read more about Tom here

 

 

Speakers:

Isaac Huang, Government Relations China, Swisse Wellness

Mr Huang is a Chinese-Australian relationship specialist and responsible for Government Relations for China

in Swisse Wellness. He is a highly experienced, versatile, strategic focused specialist, with China focused capabilities underpinned by his deep understanding of the China-Australia industry and economic environment, Chinese and Australia Government policies and initiatives relating to international trade, investment and industry development.

Prior to Swisse, Isaac held senior role in an international leading consulting firm with ten years’ experience specialising in Chinese outbound investment and strategy. Isaac has advised and assisted a number of Chinese businesses including State Owned Enterprises, successfully investing and doing business in Australia.

Liu Bing , Senior China Adviser, International Operations , Australian Trade and Investment Commission (Austrade)

Liu Bing returned to Australia in 2016, from her previous role as Acting Senior Trade Commissioner/Deputy Consul General Shanghai. Bing is now Senior China Adviser based in Austrade’s Sydney office.

While in Shanghai, Bing managed the Austrade East China network of offices by providing business opportunities and services for Australian entities in trade, education and inward investment. Bing was also the team leader of Austrade’s China financial services team, assisting Australian financial services business operations in China and enhancing Australian brand awareness and promoting Australian industry capabilities in China.

Prior to Shanghai, Bing had worked in similar roles in both Guangzhou and Beijing at the Australian Consulate in Guangzhou and the Australian Embassy in Beijing respectively from 2004-2012. Bing holds a bachelor degree of Medicine from China and a bachelor degree of Nursing from Australia.

Professor David Huang, Laboratory Head, Division: Cancer and Haematology, Walter & Eliza Hall Institute of Medical Research

Professor David Huang is a cancer researcher at the Walter and Eliza Hall Institute of Medical Research and has broad experience in academia and with industry partners in China providing insights into risk management approaches. He is Head of Strategic Alliances – Asia and has led activities to engage with top ranked universities including Tsinghua and Nanjing universities.

Professor Huang’s research is focused on discovering and developing novel anti-cancer therapies that restore the ability of cancer cells to undergo apoptosis (cell suicide), and how these can be used for treating patients with cancer.

The cancer drug Venetoclax — which will be marketed as Venclexta — resulting from Professor Huang and his team’s work has recently been approved by the TGA for patients with poor risk chronic lymphocytic leukemia (CLL), the commonest form of leukemia.

Professor Huang and his team from WEHI were awarded the Eureka Prize for Innovation in Medical Research in 2016.

Supported by:

Home

News & opinion

Member Directory

Events